Home / Health / Cancer Patient Fights OHIP for Life-Saving Treatment
Cancer Patient Fights OHIP for Life-Saving Treatment
21 Oct
Summary
- A 31-year-old woman with stage 4 cancer faces denial of out-of-country treatment.
- Ontario's health minister changed rules, restricting funding for rare drug access.
- Patients argue cost-saving measures will cost lives and are ethically questionable.
Sabrina Apitz-Grossman, 31, faces a grim prognosis with rare cancer that has spread to her lungs. Doctors recommend a U.S.-approved therapy, Tecelra, which is not available in Ontario. Her applications for out-of-country coverage through the Ontario Health Insurance Plan (OHIP) have been repeatedly denied.
Recent regulatory changes by Health Minister Sylvia Jones now limit out-of-country drug funding to cases where the treatment is already funded within Ontario but experiencing delays. This policy shift, framed as a cost-saving measure, has dashed hopes for patients like Apitz-Grossman and Kevin Nash, who also has metastatic melanoma.
Tecelra, a personalized T-cell therapy, offers a significant chance of survival for patients in Apitz-Grossman's condition. However, its cost is US$727,000, and the manufacturer has no plans to seek approval in Canada, meaning it won't undergo Ontario's review process. Other patients, like Holly Wardlow with liver cancer, are self-funding expensive treatments while awaiting reviews that may never occur.
The government's justification of protecting taxpayers and drug approval integrity is met with skepticism. Patients and their families argue that prioritizing cost savings over lives is ethically unacceptable, especially when life-saving treatments are within reach but financially inaccessible due to provincial policies.
